|Articles|June 1, 2006

LCGC Supplements

  • Special Issues-07-01-2006
  • Volume 0
  • Issue 0

Validation in Biotechnology and Well-Characterized Biopharmaceutical Products

This article describes the current situation in FDA-regulated areas, as well as characterization of these products. Finally,the author discusses the various stages of early- and late-phase product developments.
External Link - article-416293.pdf

Articles in this issue

over 19 years ago

Analytical Instrument Qualification

over 19 years ago

GMP and Phase I Clinical Trials: Streamlining the Critical Path?

over 19 years ago

Team Effort

over 19 years ago

Rated PG: Pharmaceutical Guidance Suggested

over 19 years ago

European Clinical Trial Regulations Undergo a Slow Revolution

over 19 years ago

A Practical and Cost-Effective Risk Assessment for the Validation of Commercial Laboratory Computerized Systems

over 19 years ago

Moving Biotech Products from CBER to CDER: A Work in Progress

over 19 years ago

FDA Video Interview Conducted by Jill Wechsler, Washington Bureau Chief

over 19 years ago

New Climate

over 19 years ago

2006: A Regulatory Odyssey

Newsletter

Join the global community of analytical scientists who trust LCGC for insights on the latest techniques, trends, and expert solutions in chromatography.

Subscribe Now!

Related Content